MedTrace Logo

Safety of a Hypolipidemic Agent in Healthy Normal Volunteers

NCT00685737 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-06-27

No results posted yet for this study

Summary

The Purpose of this study is to determine the safety and tolerability of 1-MNA, a drug that is intended to be used in the treatment of elevated levels of blood fats. This study will determine the way that 1-MNA is handled by the body, and will also determine its effect on commonly measured blood fat parameters.

Conditions

Interventions

DRUG

1-MNA

Capsule

DRUG

Placebo

Capsule

Sponsors & Collaborators

  • Pharmena North America

    lead INDUSTRY

Principal Investigators

  • Charles H Ballow, Pharm D. · Buffalo Clinical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00685737 on ClinicalTrials.gov